Thinly traded nano cap Akers Biosciences (AKER +62.4%) rallies on a healthy 25x surge in volume in reaction to the advancement of its COVID-19 vaccine candidate.
The company, along with collaboration partner Premas Biotech, has successfully cloned
three coronavirus antigens, Spike, Envelope and Membrane, representing
three “shots on goal” for efficacy according to Premas co-founder and
Managing Director Prabuddha Kundu.
The parties have initiated the second stage of protein expression and will provide another update later this month.
https://seekingalpha.com/news/3558624-akers-biosciences-up-62-on-advancement-of-covidminus-19-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.